We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
BioCryst Pharmaceuticals (BCRX - Free Report) shares ended the last trading session 6.1% higher at $6.81. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.2% loss over the past four weeks.
BioCryst Pharmaceuticals’ stock likely surged following its $700 million agreement to acquire Astria Therapeutics. Subject to closing, the deal will add ATXS’ lead hereditary angioedema (HAE) candidate, navenibart, a long-acting injectable therapy, to BCRX’s pipeline, enhancing its leadership in the HAE market. Investors appear encouraged by the potential for double-digit revenue growth, profit accretion, and rapid market adoption post-launch, as well as the strategic fit with the company’s existing commercialization platform. The sizable premium offered on ATXS shares also underscores the high strategic value of the acquisition.
This drugmaker is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of +185.7%. Revenues are expected to be $161.15 million, up 37.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For BioCryst, the consensus EPS estimate for the quarter has been revised 4.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BCRX going forward to see if this recent jump can turn into more strength down the road.
BioCryst is part of the Zacks Medical - Drugs industry. Ironwood Pharmaceuticals (IRWD - Free Report) , another stock in the same industry, closed the last trading session 8.8% higher at $1.61. IRWD has returned 13.9% in the past month.
Ironwood's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.09. Compared to the company's year-ago EPS, this represents a change of +350%. Ironwood currently boasts a Zacks Rank of #1 (Strong Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
BioCryst Pharmaceuticals (BCRX - Free Report) shares ended the last trading session 6.1% higher at $6.81. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.2% loss over the past four weeks.
BioCryst Pharmaceuticals’ stock likely surged following its $700 million agreement to acquire Astria Therapeutics. Subject to closing, the deal will add ATXS’ lead hereditary angioedema (HAE) candidate, navenibart, a long-acting injectable therapy, to BCRX’s pipeline, enhancing its leadership in the HAE market. Investors appear encouraged by the potential for double-digit revenue growth, profit accretion, and rapid market adoption post-launch, as well as the strategic fit with the company’s existing commercialization platform. The sizable premium offered on ATXS shares also underscores the high strategic value of the acquisition.
This drugmaker is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of +185.7%. Revenues are expected to be $161.15 million, up 37.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For BioCryst, the consensus EPS estimate for the quarter has been revised 4.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BCRX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
BioCryst is part of the Zacks Medical - Drugs industry. Ironwood Pharmaceuticals (IRWD - Free Report) , another stock in the same industry, closed the last trading session 8.8% higher at $1.61. IRWD has returned 13.9% in the past month.
Ironwood's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.09. Compared to the company's year-ago EPS, this represents a change of +350%. Ironwood currently boasts a Zacks Rank of #1 (Strong Buy).